Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA1CSR)

Drug Name

LY3499446 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting KRAS G12C mutant (KRAS G12C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotorasib	DMLSV74	Non-small-cell lung cancer	2C25	Approved	[3]
Adagrasib	DMDV4EP	Non-small-cell lung cancer	2C25	Approved	[4]
JDQ443	DMHI7CQ	Non-small-cell lung cancer	2C25	Phase 3	[5]
RG6330	DMSX5NJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
JNJ-74699157	DMY7CW1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04165031) A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation. U.S. National Institutes of Health.
2	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
3	Clinical pipeline report, company report or official report of Amgen.
4	Clinical pipeline report, company report or official report of Mirati Therapeutics.
5	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
6	Clinical pipeline report, company report or official report of Roche.